Tue. Oct 19th, 2021


Covid-19 Vaccine Updates

Protection against Pfizer’s Covid-19 vaccine is declining six to eight months after the second dose, according to data released on Wednesday, as the company tries to persuade regulators to program amplifier.

Ahead of an important meeting of the Food and Drug Administration’s advisory committee on Friday, Pfizer submitted an independent study by Kaiser Permanente in Southern California, suggesting that vaccine efficacy naturally decreases over time, “regardless of the variant”, rather as a result of the Delta tribe escaping its sting.

Pfizer provided data showing how the vaccine gradually became less effective at two-month intervals. Vaccine efficacy dropped about 6 percent every two months after the second dose, from 96.2 percent per week after complete vaccination to 83.7 percent more than four months later.

The company also cited Israeli data showing that a third jump shot restored up to 95 percent protection against Covid-19, according to documents submitted to the FDA.

Latest news about coronavirus

Follow FT’s live coverage and analysis of the global pandemic and the rapidly evolving economic crisis here.

The FDA’s advisory committee is meeting Friday to decide whether to recommend that the regulator approve a booster dose of the BioNTech / Pfizer jab, and for which populations. The FDA has already signed off on booster doses of mRNA vaccines such as Pfizer for people with a weak immune system.

Documents published by the FDA show that Pfizer asked regulators to approve a boost shot six months after people received their second shot.

In a separate review of the data from the Pfizer vaccine, the FDA said that the reduced antibody among vaccines may be related to the jump in cases seen during the summer when the Delta variant spread.

But officials said the data is not conclusive as to whether the vaccine’s ability to stop symptomatic infection is declining, a sign of internal friction within the regulator over whether boosters are needed.

“Overall, data currently indicates that currently licensed or authorized Covid-19 vaccines in the United States continue to provide protection against serious Covid-19 diseases and deaths in the United States,” the agency said in an information document also published Wednesday. is.

The Biden administration has said it wants to start rolling out a vaccine program amplifier next week along with a dozen other countries concerned about an increase in vaccine breakthrough infections.

The plan was controversial and drew criticism from two top American scientists, who recently announced their retirement from the U.S. Drug Enforcement Administration.

The scientists, Philip Krause and Marion Gruber, were this week co-authors of a report which concluded that there is not enough evidence to justify a reinforcement program at a time when vaccine supplies in other parts of the world are tightly limited. does not become.

Angela Hwang, president of Pfizer Biopharmaceuticals Group, said available data supported a reinforcement program to protect the public and to end the pandemic sooner rather than later.

‘Big picture, a boost is important, a boost is needed. This is the way we should protect individuals and the public, ”she said during the investor conference of BofA Global Healthcare on Wednesday.

While the Biden administration is preparing to decide whether it wants to give the final plan for the boost plan, the US president is also trying to start the vaccination rate of the country.

Biden will meet business leaders in the White House on Wednesday, while he wants to eliminate the administration’s support for his administration’s new vaccine mandates. The meeting is intended to provide strong support for its decision to require medium-sized and large enterprises to insist that their staff be either vaccinated or tested for Covid-19 at least once a week.

Participants include Disney CEO Bob Chapek; Brad Smith, president of Microsoft, and Joshua Bolten, head of the Business Roundtable.



Source link

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *